Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00534417 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
A Phase 2 study of Metastatic Breast Cancer, sponsored by Accelerated Community Oncology Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 10
- Study locations
NCT00534417: Completed Phase 2 study of Metastatic Breast Cancer, sponsored by Accelerated Community Oncology Research Network.
NCT00534417 is a Phase 2 study of Metastatic Breast Cancer that has completed, run by Accelerated Community Oncology Research Network. The registered enrollment target is 41 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (80% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00534417, a Phase 2 study of Metastatic Breast Cancer, has completed, sponsored by Accelerated Community Oncology Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to determine if the combination of continuous daily capecitabine with fulvestrant on a loading dose schedule will delay disease progression in metastatic breast cancer (MBC) patients.
Primary Outcome
Time to progression is defined as the time from treatment start until objective tumor progression. Progression is defined per Response Evaluation Criteria in Solid Tumors (RECIST)v1.0 guidelines as a measurable increase in the smallest diameter of any target lesion, progression of existing non-target lesions, or the appearance of 1 or more new lesions. The median time to progression is the parameter used to describe TTP.
Conditions Studied
Interventions
- DRUG fulvestrant
- DRUG capecitabine
Study Locations (10)
Georgia
- Northeast Georgia Cancer Care - Athens
- Augusta Oncology Associates - Augusta
Illinois
- Medical & Surgical Specialists - Galesburg
- Oncology Specialists - Park Ridge
Florida
- Advanced Medical Specialties - Miami
Montana
- Hematology Oncology Centers of the Northern Rockies - Billings
Nevada
- Las Vegas Cancer Center - Henderson
Pennsylvania
- The Lancaster Cancer Center, Ltd - Lancaster
Tennessee
- The West Clinic - Memphis
Virginia
- Cancer Specialists of Tidewater - Chesapeake
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-10 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
What the finished NCT00534417 record still lists
NCT00534417 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which fulvestrant is the first listed.
NCT00534417 lists 10 locations in 8 states (Georgia, Illinois, Florida).
Frequently Asked Questions
What is clinical trial NCT00534417 about?
NCT00534417 is a clinical study titled "Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer". The purpose of this study is to determine if the combination of continuous daily capecitabine with fulvestrant on a loading dose schedule will delay disease progression in metastatic breast cancer (MBC) patients.
What is the current status of trial NCT00534417?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2007-10. Estimated completion is 2011-09.
What conditions does trial NCT00534417 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT00534417?
The interventions under investigation include: fulvestrant (DRUG), capecitabine (DRUG).
Who is sponsoring clinical trial NCT00534417?
This trial is sponsored by Accelerated Community Oncology Research Network, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00534417 being conducted?
This trial has 10 study locations across Florida, Georgia, Illinois, Montana, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00534417's enrollment target sits among peer trials
41 90th of 139 higher than 48 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
- NCT04240054 · 41 participants · Phase 2
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia